StockData

Creative Medical Technology vs Alaunos Therapeutics

CELZ and TCRT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CELZ and TCRT compare

Alaunos Therapeutics is the larger company, worth 1.3 times as much as Creative Medical Technology ($4.2M against $3.1M).

Creative Medical Technology grew revenue faster over the last twelve months (−50.0% versus −50.0% for Alaunos Therapeutics).

Alaunos Therapeutics keeps more of each dollar of sales as profit, with a net margin of −133667% compared with −201355% at Creative Medical Technology.

Creative Medical Technology scores higher on the StockData Score (7 against 4 for Alaunos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCELZTCRT
Size and price
Market cap$3.1M$4.2M
Share price$0.477$1.66
Change, 1 year−84.9%−44.1%
Change, 5 years−98.5%−99.2%
Beta (5Y)4.24−2.45
Employees–1
StockData Score
Total score7 (better)4
Valuation score1 (better)0
Growth score1 (better)0
Performance score00
Health score5 (better)4
Dividend score00
Valuation
P/S1047× (better)1406×
P/B0.4× (better)6.5×
Growth
Revenue growth (TTM)−50.0%−50.0%
Revenue growth, 5Y average−48.4%–
Profitability
Gross margin66.9%–
Operating margin−208004%−135267% (better)
Net margin−201355%−133667% (better)
Return on equity−78.0% (better)−186%
Return on invested capital−4600%−489% (better)
Financial health
Debt / equity0.000.00
Current ratio12.91 (better)0.77
Altman Z-score−9.41 (better)−861.74
Piotroski F-score4 (better)3
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions5.7%3.6%
Held by insiders15.9%69.8%
Short interest, % of float1.2%24.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.